- Home
- ALEC vs ATOS Comparison
ALEC vs ATOS Comparison
Compare ALEC & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- ATOS
- Stock Information
- Founded
- ALEC 2013
- ATOS 2009
- Country
- ALEC United States
- ATOS United States
- Employees
- ALEC N/A
- ATOS N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ALEC Health Care
- ATOS Health Care
- Exchange
- ALEC Nasdaq
- ATOS Nasdaq
- Market Cap
- ALEC 124.0M
- ATOS 120.4M
- IPO Year
- ALEC 2019
- ATOS 2012
- Fundamental
- Price
- ALEC $1.50
- ATOS $0.93
- Analyst Decision
- ALEC Hold
- ATOS Strong Buy
- Analyst Count
- ALEC 9
- ATOS 3
- Target Price
- ALEC $3.40
- ATOS $6.25
- AVG Volume (30 Days)
- ALEC 4.6M
- ATOS 1.5M
- Earning Date
- ALEC 11-06-2025
- ATOS 11-12-2025
- Dividend Yield
- ALEC N/A
- ATOS N/A
- EPS Growth
- ALEC N/A
- ATOS N/A
- EPS
- ALEC N/A
- ATOS N/A
- Revenue
- ALEC $81,130,000.00
- ATOS N/A
- Revenue This Year
- ALEC N/A
- ATOS N/A
- Revenue Next Year
- ALEC $290.64
- ATOS N/A
- P/E Ratio
- ALEC N/A
- ATOS N/A
- Revenue Growth
- ALEC 46.77
- ATOS N/A
- 52 Week Low
- ALEC $0.87
- ATOS $0.55
- 52 Week High
- ALEC $6.14
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- ALEC 27.08
- ATOS 46.91
- Support Level
- ALEC $1.45
- ATOS $0.90
- Resistance Level
- ALEC $1.60
- ATOS $1.10
- Average True Range (ATR)
- ALEC 0.20
- ATOS 0.06
- MACD
- ALEC -0.20
- ATOS -0.02
- Stochastic Oscillator
- ALEC 8.45
- ATOS 8.90
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.